Market Report Source

Overview

Report Overview

In a market currently valued at US$36 billion, pharmacotherapies for conditions such as sleep disorders, addictions, depression, infertility, sexual disorders, and chronological ageing, are forecast to triple in value to over US$100 billion by 2020. Spectra`s data-intensive study, Antiageing and Life Enhancement Pharmacotherapeutics: Rejuvenating Drug Markets to 2012 and Beyond, predicts dramatic expansion based on increasing ageing populations, high unmet needs related to ageing and lifestyle dissatisfaction, unrelenting media fixation on youthfulness and image, and pharmacological innovation. With more than 90 marketed products evaluated and over 270 candidates identified in clinical development, this unique 580-page comprehensive multipart report, covering over 15 major therapy areas, provides unrivalled analysis of the enlarging dynamic market, and illustrates high-growth market sectors and prospects that may be positioned for market dominance on commercialization.

Combining extensive research methodology with analytical and strategic review, the study offers a unique insight to the scope of the product market and development pipeline and shows, for example, how ethical drugs are increasingly being used in a therapeutic switch capacity to target cosmetic antiageing and life enhancement. Furthermore, drugs in development in the field are shown to be highly sophisticated products with multiple therapeutic benefits which may revolutionize medical treatments across a number of therapy areas.

Contents of this report are also expanded upon and available by separate reports in the Spectra Compendia series

Table of Contents

CONTENTS
List of Tables
List of Figures
Company Index
Executive Summary
Objectives of the Report
Research Methodology

Chapter 1 Introduction to Antiageing and Life Enhancement Pharmacotherapeutics
Ageing and Life Enhancement
What are Antiageing and Life Enhancement Pharmacotherapeutics?
Classifying the Ageing and Lifestyle Conditions
Characteristics of Ageing and Lifestyle Conditions
Categorizing Ageing and Lifestyle Conditions
Marketed Antiageing and Life Enhancement Drugs – Ageing, Lifestyle Conditions, and Dermatology
Alopecia
Prevalence of Alopecia
Alopecia as a Lifestyle Problem
The Normal Hair Growth Cycle
Types of Alopecia
Dermal Ageing
Photodamage and Solar Radiation
Pollution and Dermal Damage
Dermal Pigmentation
Hyerpigmentation and Hypopigmentation Disorders
Biological Basis to Pigmentation: Melanogenesis and Photoprotection
Cellular Mechanisms of Melanogenesis and Photoprotection
Hyperpigmentation Disorders
Hypopigmentation Disorders
Vitiligo
Albinism
Postinflammatory Hypopigmentation
Lipodermal Disorders
Gynoid Lipodystrophy
The Development of Cellulite
Treatments Options for Cellulite
Obesity
Obesity Prevalence
Types of Obesity
Measuring and Diagnosing Obesity
Aetiological Aspects of Obesity
Physiological Aspects of Hunger and Satiety
Health Risks of Obesity
Psychosocial Aspects of Obesity – Ageing, Life Enhancement, and the Central Nervous System
Depression
Prevalence
Aetiology of Depression
Types of Depression
Major depression
Dysthymia
Bipolar Disorder
Symptoms of Depression
Anxiety Disorders
Prevalence
Addiction Disorders
Incidence of Addiction Disorders
Neurobiological Basis of Addiction
Treatment Options
Cognitive/Memory Deficits
Prevalence
Pharmacotherapy for Cognitive Impairment
Sleep Disorders
Insomnia
Prevalence of Insomnia
Causes of Insomnia
Restless Legs Syndrome
Prevalence of Restless Legs Syndrome
Circadian Rhythm Sleep Disorders
Delayed Sleep Disorders
Shift-Work Sleep Disorder
Jet-Lag Sleep Disorders
Excessive Daytime Sleepiness and Narcolepsy
Narcolepsy
Prevalence of Narcolepsy
Neurobiological Basis to Narcolepsy
Treatments for Narcolepsy
Sleep Apnoea
Obstructive Sleep Apnoea
Prevalence of Obstructive Sleep Apnoea
Therapeutics for Sleep Apnoea – Ageing, Lifestyle Conditions, and Reproductive Health
Elective Infertility – Contraception
The Birth of Contraception
Inducing Infertility via Ovulation Suppression
Combined Oral Contraceptives
Fertility Disorders
Assisted Conception – Ageing, Lifestyle Conditions, and Urology
Sexual Disorders 99
Prevalence of Sexual Dysfunction
Male Sexual Disorders
Sexual Desire Disorders
Male Erectile Dysfunction
Normal Erectile Function
Psychological Aspects of Male Erectile Dysfunction
Prevalence of Male Erectile Dysfunction
Therapeutics for Male Erectile Dysfunction
Priapism
Peyronie’s disease
Disorders of Ejaculation
Premature Ejaculation
Retarded Ejaculation
Retrograde Ejaculation
Female Sexual Dysfunction
Prevalence of Female Sexual Dysfunction
Specific Female Sexual Dysfunction Disorders
Disorders of Desire
Disorders of Arousal
Disorders of Lubrication
Persistent Sexual Arousal Syndrome
Disorders of Orgasm
Pain Disorders
Dyspareunia
Vulvodynia
Vaginismus

Chapter 2 Dermatology – Alopecia
Alopecia Drug Market Overview
Market Forecasts for Alopecia Products
Market Analysis for the Alopecia Drug Market
Propecia (Finasteride) – Merck
Rogaine/Regaine (Minoxidil) – Pfizer
Product Extension Strategy Insights for Alopecia Products
Product Extension Strategy Insights for Finasteride
Product Extension Strategy Insights for Minoxidil
Future Considerations for Drugs to Treat Alopecia
Drug Development Prospects
BIO024 – Genaderm
Other Clinical Candidates – Cutaneous Ageing
Dermal Ageing Product Market Overview
Market Forecasts for Dermal Ageing Products
Market Analysis for Cutaneous Ageing/Photodamage Products
Market Insights and Strategies for the Botulinum Toxin Sector
Direct Competition to Botox
Botulinum Toxin Products in Asia and South America
Product Extension Strategy Insights for Botulinum Toxin Products
Market Insights and Strategies for the Topical Antiageing Product Sector
Product Extension Strategy Insights for Topical Antiageing Products
Tretinoin
Isotretinoin
Tazarotene
Idebenone
Acid Peel Products
Future Considerations and Market Insights for the Cutaneous Antiageing Product Sector – Dermal Pigmentation Conditions
Market Forecasts for Dermal Pigmentation Products
Market Analysis of the Dermal Pigmentation Product Sector
Market Insights and Potential Product Development Strategies for Hyperpigmentation Conditions
Hydroquinone
Tretinoin
Azelaic Acid
Market Insights and Potential Product Development Strategies for Hypopigmentation Conditions
Induced Photoprotective Melanogenesis
Therapeutic, Prophylactic, and Cosmetic Markets for Photoprotective Melanogenesis
Solar Allergies/Polymorphous Light Eruption
Other Hypopigmentation Conditions
Skin Cancer Prophylaxis
Cosmetic-Medical Indications
Future Considerations and Market Outlook for the Dermal Pigmentation Therapy Area – Lipodermal Conditions
Gynoid Lipodystrophy (Cellulite)
Novel Pharmacotherapeutics for Cellulite
BIO303 – Enhance Biotech/Bioaccelerate
Phosphatidylcholine (Lecithin)
Redeveloping Old Molecules for New Cosmetic Indications
Obesity
Market Analysis for Antiobesity Drugs
Market Forecasts for Antiobesity Drugs
Antiobesity Product Extension Strategies and Insights
Sibutramine – (Meridia/Reductil) Abbot Laboratories
Market Outlook for Sibutramine
Orlistat
Class Competition – ATL-962 (Cetilistat) Alizyme
Product Extension Strategy Insights for Orlistat 1
Antiobesity Drugs at the Premarket Authorization Stage
Rimonabant
Safety and Efficacy Data
Lipodermal Disorders – Future Considerations and Market Insights
New Weight Regulation and Lipid Metabolism Market Opportunities

Chapter 3 Central Nervous System/Psychiatry – Psychological Disorders: Depression and Anxiety
Market Overview of Drugs to Treat Depression and Anxiety Disorders
Market Analysis and Insights for Drugs to Treat Depressive Illnesses
Market Analysis: Antidepressant Therapy Area
Prozac (Fluoxetine) – Eli Lilly
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Cymbalta (Duloxetine) – Eli Lilly/Boehringer Ingelheim
Product Overview
Indications and Supplementary Labelling
Sales Prospects
Commercial Outlook
Zoloft/Lustral (Sertraline) – Pfizer
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Seroxat/Paxil/Deroxat (Paroxetine) – GlaxoSmithKline
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Wellbutrin (Bupropion) – GlaxoSmithKline
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Effexor (Venlafaxine) – Wyeth
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Remeron/Zispin (Mirtazapine) – Organon/Akzo Nobel
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Cipramil/Celexa (Citalopram) – Lundbeck/Forest Laboratories
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Cipralex/Lexapro (Escitalopram) – Lundbeck/Forest
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Future Considerations and Market Insights for the Antidepressant Market
Pipeline Antidepressants
Pipeline Focus
Valdoxan (Agomelatine) – Servier – Pharmacotherapeutics for Cognitive/Memory Deficits
Future Market Focus – Age-Related Cognitive Decline
Companies Developing Drugs for Memory and Cognitive Enhancement – Behavioural Disorders: Addictions
Market Overview for Addiction Disorders
Market Forecasts by Therapeutic Area
Alcohol Addiction
Narcotic Addiction
Tobacco Addiction
Market Forecasts for Addiction Disorders
Market Analysis of Drugs to Treat Addiction Disorders
Alcohol Addiction
Alcohol Addiction Pharmacotherapies
Acamprosate (Campral) – Merck/Forest Laboratories
Mechanisms of Action/Efficacy
Sales Estimates for Campral
Product Line Extension Possibilities
Disulfiram (Antabuse) – Alpharma
Mechanism of Action/Efficacy
Sales Estimates for Disulfiram
Naltrexone Hydrochlride
Mechanisms of Action/Efficacy
Reformulation – Vivitrol, Alkermes/Cephalon
Sales Estimates for Naltrexone
Pipeline Focus
Naltrexone Depot – Drug Abuse Sciences, France
Nalmefene – BioTie Therapies, Finland
Alcohol Addiction – Market Insights and Future Considerations
Narcotic Addiction Pharmacotherapeutics
Cocaine Addiction
Mechanisms of Action of Cocaine
Future Therapeutics for Cocaine Addiction
Vaccine Therapy Focus – Xenova
COC-AB/DAS-431 – Drug Abuse Sciences
Opiate Addiction
Drug Substitute Therapies
Subutex/Subroxone (Buprenorphine) – Schering-Plough/Reckitt Benckiser
Mechanisms of Action/Efficacy
Reformulation
Sales Estimates
Methadone
Mechanisms of Action/Efficacy
Sales Estimates
Drugs to Control Opiate Withdrawal Symptoms
Brittofex (Lofexidine) – Britannia Pharmaceuticals
Mechanisms of Action/Efficacy
Sales Estimates
Naltrexone
Potential Reformulation
Future Drugs to Treat Opiate Addiction
Probuphine – Titan Pharmaceuticals
Buprenorphine Depot – Drug Abuse Sciences
Narcotic Addiction – Market Insights and Future Considerations
Emerging Drug Addiction Focus
Methamphetamine/Phencyclidine Abuse and Dependency
InterveXion Therapeutics
Outlook for Pharmacotherapeutic Markets Related to Alcohol and Substance Abuse
Smoking Addiction
Prevalence and Mortality Statistics
Nicotine – Mechanism of Action
Nicotine Dependency and Smoking Cessation
Smoking and Health Consequences
Healthcare Costs of Smoking Addiction
Smoking Addiction Pharmacotherapeutics
Market Analysis of Smoking Cessation Pharmacotherapeutics
Nicotine Replacement Therapies
Nicorette/Nicotrol – Pfizer
Sales Estimates
NiQuitin/NicoDerm/Nicorette/Nicabate – GlaxoSmithKline
Sales Estimates
Nicotinell/Habitrol – Novartis
Sales Estimates
Other Smoking Cessation Pharmacotherapies
Zyban (Bupropion) – GlaxoSmithKline
Sales Estimates
Future Drugs to Treat Smoking Addiction
Late-Stage Development Product Focus
Rimonabant (Acomplia) – Sanofi-Aventis
Varenicline – Pfizer
Vaccine Focus
NicVAX – Nabi Biopharmaceuticals
TA-NIC – Xenova
Smoking Addiction – Market Insights and Future Considerations
Drugs in the Pipe – Behavioural/CNS: Sleep Disorders
Market Overview for Sleep Disorders
Insomnia
Wake-Promotion
Restless Legs Syndrome
Market Analysis for Drugs to Treat Sleep Disorders – Insomnia
Market Analysis for the Insomnia Pharmacotherapies
Key Insomnia Drugs
Ambien/Stilnox/Stilnoct/Myslee (Zolpidem) – Sanofi-Aventis
Mechanism of Action
Efficacy
Reformulation
Sales Estimates
Commercial Outlook
Halcion (Triazolam) – Pfizer
Mechanism of Action
Reformulation
Sales Estimates
Commercial Outlook
Lunesta (Eszopiclone) – Sepracor
Mechanism of Action
Sales Estimates
Commercial Outlook
Rozerem (Ramelteon) – Takeda Pharmaceuticals
Mechanism of Action
Efficacy
Sales Estimates
Commercial Outlook
Sonata (Zaleplon) – Wyeth/King Pharmaceuticals
Mechanism of Action
Efficacy
Reformulation
Sales Estimates
Commercial Outlook
Premarket Focus – Late-Stage Development Drugs for Insomnia
Indiplon – Neurocrine Biosciences/Pfizer
Mechanisms of Action
Formulation Development
Efficacy
Commercial Prospects
Gaboxadol – Lundbeck/Merck & Co
Mechanisms of Action
Efficacy
Commercial Prospects
Other Pipeline Drug Candidates for Insomnia
Silenor (Doxepin) – Somaxon Pharmaceuticals
Posidorm – Alliance Pharma
Future Considerations and Market Outlook for the Insomnia Drug Market – Wake-Promotion
Narcolepsy/Excessive Daytime Sleepiness
Market Analysis for Key Drugs for Narcolepy/Excessive Daytime Sleepiness
Provigil (Modafanil) – Cephalon
Mechanism of Action
Efficacy
Supplementary Indications
Reformulation
Sales Estimates
Commercial Prospects
Xyrem (Sodium oxybate) – Orphan Medical/Jazz Pharmaceuticals
Efficacy
Side Effects
Sales Estimates
Commerical Prospects
Future Considerations and Market Outlook for Wake-Promoting Drugs – Restless Legs Syndrome
Requip/Adartrel/Repreve (Ropinirole) – GlaxoSmithKline
Mechanisms of Action
Efficacy
Sales Estimates
Commercial Outlook
Drugs in Development for Restless Legs Syndrome
Premarket Focus: Pramipexole – Boehringer Ingelheim
Efficacy
Commerical Prospects – Sleep Apnoea – An Emerging High-Growth Sector
Obstructive Sleep Apnoea-Hyponoea Syndrome – An Underdiagnosed Problem
Commercial Insights
Pipeline Focus
Future Considerations and Market Insights for Drugs to Treat Sleep Disorders

Chapter 4 Reproductive Health: Contraception and Infertility
Reproductive Health Market Overview
Market Analysis for Contraception and Infertility
Infertility
Hormonal Contraception
Contraceptive Formulations
Combined Oestrogen-Progestogen Contraceptives
Progestogen-Only Contraceptives – Product Market for Hormonal Contraceptives
Janssen-Cilag/Ortho-McNeil/Johnson & Johnson
Key Product and Portfolio Review
Sales Estimates and Product Market Outlook
Organon/Akzo Nobel
Key Product and Portfolio Review
Pipeline Focus
EMM 310066
Male Contraception – Organon/Schering
Sales Estimates and Product Market Outlook
Pharmacia/Pfizer
Key Product and Portfolio Review
Sales Estimates and Product Market Outlook
Schering/Berlex
Key Product and Portfolio Review
Pipeline Focus
Yaz
Contraceptive Patch
E2/DNG Pill
Male Contraception
Sales Estimates and Product Market Outlook
Wyeth
Key Product and Portfolio Review
Sales Estimates and Product Market Outlook
Barr Laboratories
Key Product and Portfolio Review
Pipeline Focus
Sales Estimates and Product Market Outlook
Contraceptives in Research and Development
Future Considerations and Outlook for the Contraceptive Product Market – Infertility Pharmacotherapeutics
Market Overview for Infertility Drugs
Pharmacotherapies for Infertility
Mechanism of Action of Infertility Pharmacotherapeutics
Product Market Analysis for Infertility Pharmacotherapeutics
AstraZeneca
Key Product and Portfolio Review
Sales Estimates and Product Market Outlook
Ferring
Key Product and Portfolio Review
Pipeline Focus
Sales Estimates and Product Market Outlook
Organon
Key Product and Portfolio Review
Pipeline Focus
Sales Estimates and Product Market Outlook
Serono
Key Product and Portfolio Review
Pipeline Focus
Sales Estimates and Product Market Outlook
Future Considerations and Market Insights for Infertility Pharmacotherapeutics
Infertility Drugs in Research and Development
Novel Female Infertility Pharmacotherapeutics
Novel Male Infertility Pharmacotherapeutics

Chapter 5 Urology: Sexual Disorders
Sexual Disorders Market Overview
Market Analysis for Sexual Disorder Pharmacotherapeutics
Testosterone Replacement
Erectile Dysfunction
Female Sexual Disorders – Male Sexual Disorders
Androgen Deficiency and Disorders of Desire
The Andropause
Product Market Analysis for Androgen Deficiency and Disorders of Desire
Columbia Labs/Ardana
Sales Estimates and Market Outlook
Organon
Sales Estimates and Market Outlook
Schering
Sales Estimates and Market Outlook
Solvay Pharmaceuticals
Sales Estimates and Market Outlook
Drugs in Research and Development for Androgen Deficiency and Andropause
Future Considerations for Drugs to Treat Androgen Deficiencies Associated with Sexual Disorders and Andropause – Male Erectile Dysfunction
Uprima/Ixense (Apomorphine) – Abbott/TAP Pharmaceuticals
Sales Estimates and Market Outlook
Levitra (vardenafil) – Bayer/GlaxoSmithKline
Sales Estimates and Market Outlook
Cialis (tadalafil) – Lilly/ICOS
Sales Estimates and Market Outlook
Viagra (Sildenafil); Caverject (Alprostadil) – Pharmacia/Pfizer
Sales Estimates and Market Outlook
Viridal/Edex (Alprostadil) – Schwarz
Sales Estimates and Market Outlook
Invicorp (Phentolamine Mesilate/Vasoactive Intestinal Polypeptide) – Senetek/Ardana
Sales Estimates and Market Outlook
MUSE (Alprostadil) – Vivus
Sales Estimates and Market Outlook
Pipeline Focus – Avanafil
Future Considerations and Market Outlook for Drugs to Treat Erectile Dysfunction
Pipeline Drugs and Market Prospects in the Sexual Disorder Market
Erectile Dysfunction Drug Pipeline – Emerging Sexual Disorder Therapy Areas
Premature Ejaculation
Neuronal Mechanism of Premature Ejaculation
Drugs in Development for Premature Ejaculation
Future Considerations and Market Outlook for Drugs to Treat Premature Ejaculation – Female Sexual Disorders
An High-Growth Market Opportunity?
Drugs in Development for Female Sexual Disorders
Future Considerations and Market Outlook for Drugs to Treat Female Sexual Dysfunction

Chapter 6 Drugs in Research and Development
Introduction – Dermatology
Alopecia
Research and Development Overview
Dermal Ageing
Research and Development Overview
Pigmentation Conditions
Research and Development Overview
Lipodermal Conditions
Obesity
Research and Development Overview – Central Nervous System/Psychiatry
Psychological Disorders: Depression and Anxiety
Research and Development Overview
Psychological Disorders: Cognitive/Memory Impairments
Research and Development Overview
Behavioural Disorders: Addictions
Research and Development Overview
Sleep Disorders
Research and Development Overview – Reproductive Health: Contraception and Infertility
Contraception
Research and Development Overview
Infertility
Research and Development Overview – Sexual Disorders
Male Sexual Disorders
Research and Development Overview
Female Sexual Dysfunction
Research and Development Overview

Chapter 7 Market Analysis, Therapy Forecasting, and Prospect Mining – Introduction: Data Analysis, Therapy Forecasting, and Prospect Mining
The Antiageing and Life Enhancement Pharmacotherapeutics Market
Market Growth in the Antiageing and Life Enhancement Dug Market
Subsector Data Analysis
Market Analysis and Therapy Forecasting
Dermatology: Alopecia, Dermal Ageing, Pigmentation Disorders and Lipodermal Conditions
Therapy Area Forecasts
Market Share of Dermatological Therapy Areas
CNS/Psychiatry: Depression/Anxiety, Addictions, and Sleep-Wake Disorders
Therapy Area Forecasts
Market Share of CNS Therapy Areas
Reproductive Medicine: Contraception and Infertility
Therapy Area Forecasts
Market Share of Reproductive Medicine Therapy Areas
Urology: Sexual Disorders
Therapy Area Forecasts
Market Share of Male Sexual Disorder Market – Comparative Analysis: Product Sales
Dermatology Therapy Areas
CNS Therapy Areas
Reproductive Medicine Therapy Areas
Urology: Sexual Disorder Therapy Areas – Prospect Mining
Dermatological Drug Prospects in the Antiageing and Life Enhancement Therapy Market
Alopecia
Dermal Ageing
Dermal Pigmentation
Lipodermal Conditions
Central Nervous System Drug Prospects in the Antiageing and Life Enhancement
Therapy Market
Depression and Anxiety
Cognitive/Memory Impairment
Addictions
Sleep Disorders
Reproductive Health Drug Prospects in the Antiageing and Life Enhancement Therapy Market
Contraception
Infertility
Sexual Disorder Drug Prospects in the Antiageing and Life Enhancement Therapy Market
Androgen Deficiency/Testosterone Replacement
Erectile Dysfunction and Premature Ejaculation
Female Sexual Disorders
Top Prospects in the Antiageing and Life Enhancement Therapy Market
Novel Indications
Therapy Area Forecasts 2012 and 2020

Chapter 8 Report Synopsis – Dermatology
Alopecia – Key Data Points
Dermal Ageing and Pigmentation Disorders – Key Data Points
Lipodermal Conditions – Key Data Points – Central Nervous System
Depression/Anxiety and Cognitive Impairment – Key Data Points
Addictions – Key Data Points
Sleep Disorders and Wake Promotion – Key Data Points – Reproductive Health
Contraception Data – Key Data Points
Infertility – Key Data Points – Sexual Disorders
Male Sexual Disorders – Key Data Points
Female Sexual Disorders – Key Data Points – The Antiageing and Life Enhancement Drug Market
Key Market Data Points – Glossary and Abbreviations – Bibliography and Reference Sources

List of Tables
Table 1.1 Characteristics Related to Ageing and Lifestyle Conditions
Table 1.2 Ageing and Lifestyle Conditions Categorized by Medical Specialty
Table 1.3 Marketed Antiageing and Life Enhancement Drugs, 2005
Table 1.4 Types of Alopecia
Table 1.5 Features of Intrinsic Chronological Cutaneous Ageing and Photoageing
Table 1.6 Factors Associated with Dermal Ageing
Table 1.7 Types of Solar Radiation
Table 1.8 Common Hyperpigmentation Disorders
Table 1.9 Types of Hypopigmentation Disorders
Table 1.10 Calculating Body Mass Index
Table 1.11 Aetiological Factors Associated with Obesity
Table 1.12 Health Risks and Comorbidities Associated with Obesity
Table 1.13 Psychological, Behavioural, and Socioenvironmental Factors Associated with Obesity
Table 1.14 Role of Neurotransmitters in Depression
Table 1.15 Symptoms of Depression and Bipolar Disorder/Mania
Table 1.16 Major Anxiety Disorders
Table 1.17 Neurotransmitter Systems Associated with Addiction
Table 1.18 Drugs of Abuse and their Associations with Neurotransmitter Systems
Table 1.19 Causes of Dementia
Table 1.20 Insomnia Categorized by Duration of Symptoms
Table 1.21 Causes of Insomnia
Table 1.22 Symptoms of Narcolepsy
Table 1.23 Medical and Surgical Treatment Options for Sleep Apnoea
Table 1.24 Global Prevalence Rates of Oral Contraceptive Use
Table 1.25 Popular Combined Oral Contraceptives, 2005
Table 1.26 Biological Causes of Infertility
Table 1.27 Assisted Conception Techniques
Table 1.28 Male and Female Sexual Dysfunction Disorders
Table 1.29 Medical and Surgical Conditions Associated with Erectile Dysfunction
Table 1.30 Therapeutic Options for Male Erectile Dysfunction, 2005
Table 2.1 Estimated Global Sales & Forecasts of Drugs for Alopecia (US$m), 2004-2012
Table 2.2 Estimated Global Sales & Forecasts of Dermal Antiageing Products, 2004-2012
Table 2.3 Topical Antiageing/Photodamage Products, 2005
Table 2.4 Estimated Global Sales & Forecasts of Products for Pigmentation Conditions, 2004-2012
Table 2.5 Pharmaceutical Products to Treat Common Dermal Pigmentation, 2005
Table 2.6 Estimated Global Sales & Forecasts of Antiobesity Drugs, 2004-2012
Table 3.1 Estimated Global Sales & Forecasts of Leading Antidepressants, 2004-2012
Table 3.2 Estimated Annual Growth Rates of Leading Antidepressants (%), 2004-2012
Table 3.3 Leading Antidepressants Ranked by Sales, 2005 & 2012 (est.)
Table 3.4 Primary and Secondary Indications for Antidepressants
Table 3.5 Estimated Sales (US$) and Annual Growth (%) of Prozac, 2005-2012
Table 3.6 Estimated Sales (US$) and Annual Growth (%) of Cymbalta, 2005-2012
Table 3.7 Estimated Sales (US$) and Annual Growth (%) of Zoloft, 2005-2012
Table 3.8 Estimated Sales (US$) and Annual Growth (%) of Seroxat/Paxil, 2005-2012
Table 3.9 Estimated Sales (US$) and Annual Growth (%) of Wellbutrin, 2005-2012
Table 3.10 Estimated Sales (US$) and Annual Growth (%) of Effexor, 2005-2012
Table 3.11 Estimated Sales (US$) and Annual Growth (%) of Remeron, 2005-2012
Table 3.12 Estimated Sales (US$) and Annual Growth (%) of Cipramil/Celexa, 2005-12
Table 3.13 Estimated Sales (US$) and Annual Growth (%) of Cipralex/Lexapro, 2005-12
Table 3.14 Drugs in Development for Cognitive and Memory Impairment, 2005
Table 3.15 Estimated Global Sales, Forecasts, and Growth of Key Drugs to Treat Addictions, 2004-2012
Table 3.16 Physiological Consequences of the Disulfiram-Alcohol Reaction
Table 3.17 Estimated Sales and Annual Percentage Growth of Smoking Cessation Therapies, 2004-2012
Table 3.18 Drugs in Development for Smoking Cessation, 2005
Table 3.19 Estimated Global Sales & Forecasts of Leading Drugs for Sleep Disorders, 2004-2012
Table 3.20 Marketed Drugs to Treat Insomnia, 2005
Table 3.21 Drugs in Development for Restless Legs Syndrome, 2005
Table 4.1 Estimated Global Sales & Forecasts of Leading Hormonal Contraceptives and Infertility Drugs, 2004-2012
Table 4.2 Selection of Contraceptives Segmented by Formulation and Delivery Route, 2005
Table 4.3 Johnson & Johnson’s Hormonal Contraceptive Product Portfolio, 2005
Table 4.4 Estimated Sales (US$) and Annual Growth (%) of Ortho-McNeil/ Johnson & Johnson’s Hormonal Contraceptive Portfolio, 2005-2012
Table 4.5 Organon/Akzo Nobel’s Hormonal Contraceptive Product Portfolio, 2005
Table 4.6 Estimated Sales (US$) and Annual Growth (%) of Organon/Akzo Nobel’s Hormonal Contraceptive Portfolio, 2005-2012
Table 4.7 Pfizer’s Hormonal Contraceptive Product Portfolio, 2005
Table 4.8 Estimated Sales (US$) and Annual Growth (%) of Pfizer’s Hormonal Contraceptive Portfolio, 2005-2012
Table 4.9 Schering/Berlex’ Hormonal Contraceptive Product Portfolio, 2005
Table 4.10 Schering/Berlex’ Pipeline Contraceptive Candidates, 2005
Table 4.11 Estimated Sales (US$) and Annual Growth (%) of Schering/Berlex’ Hormonal Contraceptive Portfolio, 2005-2012
Table 4.12 Wyeth’s Hormonal Contraceptive Product Portfolio, 2005
Table 4.13 Estimated Sales (US$) and Annual Growth (%) of Wyeth’s Hormonal Contraceptive Portfolio, 2005-2012
Table 4.14 Barr’s Hormonal Contraceptive Product Portfolio, 2005
Table 4.15 Estimated Sales (US$) and Annual Growth (%) of Barr’s Hormonal Contraceptive Portfolio, 2005-2012
Table 4.16 Pipeline Hormonal Contraceptives, 2005
Table 4.17 Pharmacotherapies for Infertility, 2005
Table 4.18 AstraZeneca’s Hormonal Infertility Product Portfolio, 2005
Table 4.19 Estimated Global Sales (US$) and Annual Growth (%) of AstraZeneca’s Hormonal Infertility Products, 2005-2012
Table 4.20 Ferring’s Infertility Product Portfolio, 2005
Table 4.21 Estimated Global Sales (US$) and Annual Growth (%) of Ferring’s Infertility Products, 2005-2012
Table 4.22 Organon’s Hormonal Infertility Product Portfolio, 2005
Table 4.23 Estimated Global Sales (US$) and Annual Growth (%) of Organon’s Hormonal Infertility Products, 2005-2012
Table 4.24 Serono’s Hormonal Infertility Product Portfolio, 2005
Table 4.25 Estimated Global Sales (US$) and Annual Growth (%) of Serono’s Hormonal Infertility Products, 2005-2012
Table 4.26 Drugs in Research and Development for Infertility, 2005-11-15
Table 5.1 Global Sales & Forecasts of Leading Drugs for Male Sexual Disorders, 2004-2012
Table 5.2 Marketed Drugs for Androgen Deficiency and Male Erectile Dysfunction, 2005
Table 5.3 Symptoms of Andropause
Table 5.4 Estimated Sales (US$) and Annual Growth (%) of Striant, 2005-2012
Table 5.5 Estimated Sales (US$) and Annual Growth (%) of Organon’s Androgen Replacement Therapy Products, 2005-2012
Table 5.6 Estimated Sales (US$) and Annual Growth (%) of Schering’s Andrology Product Portfolio, 2005-2012
Table 5.7 Estimated Sales (US$) and Annual Growth (%) of Androgel, 2005-2012
Table 5.8 Drugs in Development for Androgen Deficiency and Andropause, 2005
Table 5.9 Estimated Sales (US$) and Annual Growth (%) of Uprima/Ixense, 2005-2012
Table 5.10 Estimated Sales (US$) and Annual Growth (%) of Levitra, 2005-2012
Table 5.11 Estimated Sales (US$) and Annual Growth (%) of Cialis, 2005-2012
Table 5.12 Estimated Sales (US$) and Annual Growth (%) of Pfizer’s Erectile Dysfunction Product Portfolio, 2005-2012
Table 5.13 Estimated Sales (US$) and Annual Growth (%) of Viridal/Edex, 2005-2012
Table 5.14 Estimated Sales (US$) and Annual Growth (%) of Invicorp, 2005-2012
Table 5.15 Estimated Sales (US$) and Annual Growth (%) of Muse, 2005-2012
Table 5.16 Drugs in Development for Male Erectile Dysfunction, 2005
Table 5.17 Drugs in Development for Premature Ejaculation, 2005
Table 5.18 Drugs in Development for Female Sexual Dysfunction, 2005
Table 6.1 Drugs in Development for Alopecia, 2005
Table 6.2 Drugs in Development for Dermal Ageing, 2005
Table 6.3 Drugs in Development for Pigmentation Disorders, 2005
Table 6.4 Drugs in Development for Gynoid Lipodystrophy (Cellulite), 2005
Table 6.5 Drugs in Development for Obesity, 2005
Table 6.6 Drugs in Development for Appetite Stimulation and Lipodystrophy, 2005
Table 6.7 Drugs in Development for Depression and Anxiety, 2005
Table 6.8 Drugs in Development for Cognitive and Memory Impairment, 2005
Table 6.9 Drugs in Development for Alcohol and Narcotic Addictions, 2005
Table 6.10 Drugs in Development for Nicotine Addiction, 2005
Table 6.11 Drugs in Development for Sleep Disorders, 2005
Table 6.12 Female Oral Contraceptives in Development, 2005
Table 6.13 Nonoral Female Contraceptives in Development, 2005
Table 6.14 Male Contraceptives in Development, 2005
Table 6.15 Drugs in Development for Infertility, 2005
Table 6.16 Drugs in Development for Male Androgen Deficiency and Andropause, 2005
Table 6.17 Drugs in Development for Male Erectile Dysfunction and Premature Ejaculation, 2005
Table 6.18 Drugs in Development for Female Sexual Dysfunction, 2005
Table 7.1 World Market for Antiageing and Life Enhancement Drugs (US$m), 2004-2012
Table 7.2 Antiageing and Life Enhancement Therapy Areas Ranked by Market Share, 2005 & 2012
Table 7.3 Global Drug Market for Dermatological Conditions Associated with Ageing and Lifestyle Dysfunction (US$m), 2004-2012
Table 7.4 Global Drug Market for CNS Conditions Associated with Ageing and Lifestyle Dysfunction (US$m), 2004-2012
Table 7.5 Global Drug Market for Hormonal Contraception and Infertility (US$m), 2004-2012
Table 7.6 Global Market for Male Sexual Disorders (US$m), 2004-2012
Table 7.7 Novel Indications in the Antiageing and Life Enhancement Therapy Drug Market, 2005
Table 7.8 Therapy Area Forecasts for the Global Antiageing and Life Enhancement Drug Market, 2012 and 2020

List of Figures
Figure 1.1 Factors Associated with Ageing and Lifestyle Conditions
Figure 1.2 Factors Involved in Normal Body Weight Regulation
Figure 1.3 Prevalence of Alcohol, Smoking, and Illicit Drug Abuse in UK and US Populations, 2002-2004
Figure 1.4 Lifestyle Disorder Characteristics Associated with Contraception
Figure 1.5 Lifestyle Factors Affecting Fertility
Figure 2.1 Projected Growth Rates for Alopecia Drugs, 2005-2012
Figure 2.2 Estimated Global Sales of Alopecia Drugs, 2004-2012
Figure 2.3 Projected Growth Rates for Cutaneous Antiageing Products, 2005 & 2012
Figure 2.4 Estimated Global Sales of Dermal Antiageing Products, 2004-2012
Figure 2.5 Projected Growth Rates of Products for Pigmentation Conditions, 2005 & 2012
Figure 2.6 Estimated Global Sales of Products for Pigmentation Conditions, 2004-2012
Figure 2.7 Projected Growth Rates of Current Antiobesity Drugs, 2005-2012
Figure 2.8 Estimated Global Sales of Antiobesity Drugs, 2004-2012
Figure 2.9 Main Drivers of Growth in the Antiobesity Pharmacotherapeutic Market
Figure 3.1 Estimated Global Sales of Leading Antidepressants, 2005 & 2012
Figure 3.2 Estimated Market Share of Leading Antidepressants, 2005 & 2012
Figure 3.3 Estimated Sales of Addiction Drugs Segmented by Therapeutic Area, 2004-2012
Figure 3.4 Estimated Global Sales of Leading Addiction Drugs by Therapy Area, 2005 & 2012
Figure 3.5 Estimated Sales and Forecasts of Sleep Disorder Drugs Segmented by Therapeutic Area, 2004-2012
Figure 3.6 Estimated Global Market Share of Sleep Disorder Drugs by Therapy Area, 2005 & 2012
Figure 4.1 Estimated Sales and Forecasts of Hormonal Contraceptives and Infertility Drug Sectors, 2004-2012
Figure 4.2 Estimated Global Market Share for Hormonal Contraceptives and Infertility Drug Sectors, 2005 & 2012
Figure 5.1 Estimated Sales and Forecasts of Leading Drugs for Male Sexual Disorders, 2004-2012
Figure 5.2 Global Market Share of Leading Drugs for Male Sexual Disorders, 2005 & 2012
Figure 7.1 Antiageing and Life Enhancement Market Segmented by Specialty Area, 2005 & 2012
Figure 7.2 Annual Growth Rates of Antiageing and Life Enhancement Drug Therapy Specialty Areas Between 2005 and 2012
Figure 7.3 Antiageing and Life Enhancement Market Segmented by Therapy Area, 2005 & 2012
Figure 7.4 Dermatological Therapy Area Forecasts, 2005 & 2012 (US$m)
Figure 7.5 Market Share of Dermatological Therapy Areas, 2005 & 2012
Figure 7.6 CNS Therapy Area Forecasts, 2005 & 2012 (US$m)
Figure 7.7 Market Share of CNS Therapy Areas, 2005 & 2012
Figure 7.8 Hormonal Contraceptive and Infertility Therapy Area Forecasts, 2005 & 2012 (US$m)
Figure 7.9 Market Share of Hormonal Contraception and Infertility Therapy Areas, 2005 & 2012
Figure 7.10 Therapy Area Forecasts for Male Testosterone Replacement and Erectile Dysfunction, 2005 & 2012 (US$m)
Figure 7.11 Market Share of Male Testosterone Replacement (Desire/Arousal Conditions) and Erectile Dysfunction Therapy Areas, 2005 & 2012
Figure 7.12 Comparative Analysis of Leading Dermatology Products, 2004-2012 (US$m)
Figure 7.13 Comparative Analysis of Leading CNS Products, 2004-2012 (US$m)
Figure 7.14 Comparative Analysis of Leading Contraceptives and Infertility Drug Products, 2004-2012 (US$m)
Figure 7.15 Comparative Analysis of Leading Testosterone Replacement Therapies and Erectile Dysfunction Products, 2004-2012 (US$m)
Figure 7.16 Key Alopecia Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
Figure 7.17 Key Dermal Ageing Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
Figure 7.18 Key Dermal Pigmentation Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
Figure 7.19 Key Lipodermal Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
Figure 7.20 Key Antidepressant Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
Figure 7.21 Key Cognitive/Memory Impairment Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
Figure 7.22 Key Addiction Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
Figure 7.23 Key Sleep-Wake Promotion Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
Figure 7.24 Key Contraception Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
Figure 7.25 Key Infertility Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
Figure 7.26 Key Testosterone Replacement Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
Figure 7.27 Key Erectile Dysfunction and Premature Ejaculation Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
Figure 7.28 Key Female Sexual Dysfunction Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
Figure 7.29 Top Ten Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005